{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:21:24Z","timestamp":1794662484022,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1153279"],"award-info":[{"award-number":["OPP1153279"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.07.088","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T12:11:35Z","timestamp":1566475895000},"page":"5909-5919","source":"Crossref","is-referenced-by-count":22,"title":["The art of partnerships for vaccines"],"prefix":"10.1016","volume":"37","author":[{"given":"Sonia","family":"Pagliusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.07.088_b0005","unstructured":"WHO Thirteenth general programme of work 2019\u22122023. Available at https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/324775\/WHO-PRP-18.1-eng.pdf."},{"key":"10.1016\/j.vaccine.2019.07.088_b0010","unstructured":"WHO Emergencies. Availableat http:\/\/www.who.int\/emergencies\/crises\/en\/"},{"key":"10.1016\/j.vaccine.2019.07.088_b0015","unstructured":"WHO Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines. TRS, No. 996, 2016, Annex 8 https:\/\/www.who.int\/medicines\/publications\/pharmprep\/WHO_TRS_996_web.pdf."},{"key":"10.1016\/j.vaccine.2019.07.088_b0020","unstructured":"UN Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages. Available from: https:\/\/www.un.org\/sustainabledevelopment\/health\/."},{"issue":"45","key":"10.1016\/j.vaccine.2019.07.088_b0025","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2018.06.012","article-title":"Challenges to sustainable immunization systems in Gavi transitioning countries","volume":"36","author":"Cernuschi","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.088_b0030","unstructured":"Univercells\u2019 modular manufacturing platforms for vaccines, antibodies or proteins. Available from: https:\/\/www.univercells.com\/our-technology\/."},{"issue":"17","key":"10.1016\/j.vaccine.2019.07.088_b0035","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2017.09.029","article-title":"A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib\/Hep B-IPV (EasySix) to licensed combination vaccines in healthy infants","volume":"36","author":"Mohanty","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.07.088_b0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/21645515.2017.1412020","article-title":"Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges","volume":"14","author":"Mustapha","year":"2018","journal-title":"Hum Vaccines Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2019.07.088_b0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.biologicals.2013.12.001","article-title":"Process development and immunogenicity studies on a serogroup 'X' Meningococcal polysaccharide conjugate vaccine","volume":"42","author":"Chilukuri","year":"2014","journal-title":"Biologicals"},{"issue":"10","key":"10.1016\/j.vaccine.2019.07.088_b0050","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S1473-3099(18)30400-6","article-title":"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study","volume":"18","author":"Chen","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.088_b0055","unstructured":"Collaborators G.B.D.D.D. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18(11):p. 1211\u201328."},{"issue":"8","key":"10.1016\/j.vaccine.2019.07.088_b0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa1706804","article-title":"Human neonatal rotavirus vaccine (RV3-BB) to Target Rotavirus from Birth","volume":"378","author":"Bines","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2019.07.088_b0065","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(17)30242-6","article-title":"Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial","volume":"17","author":"Groome","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.07.088_b0070","unstructured":"Sanofi Pasteur. Product monograph: IMOGAM\u00ae Rabies Pasteurized - Rabies Immune Globulin, Pasteurized (Human) Solution for Injection. Available from: https:\/\/www.vaccineshoppecanada.com\/document.cfm?file=imogam_rabies_e.pdf"},{"issue":"9","key":"10.1016\/j.vaccine.2019.07.088_b0075","doi-asserted-by":"crossref","first-page":"e0006807","DOI":"10.1371\/journal.pntd.0006807","article-title":"Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: a modelling study","volume":"12","author":"Cooper","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.07.088_b0080","doi-asserted-by":"crossref","unstructured":"Katzelnick LC, Harris E, and Participants in the Summit on Dengue Immune Correlates of, Immune correlates of protection for dengue: state of the art and research agenda. Vaccine 2017;35(36):p. 4659\u201369.","DOI":"10.1016\/j.vaccine.2017.07.045"},{"issue":"50","key":"10.1016\/j.vaccine.2019.07.088_b0085","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1016\/j.vaccine.2015.09.105","article-title":"Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine","volume":"33","author":"Precioso","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.07.088_b0090","unstructured":"WHO WHO-National Control Laboratory Network for Biologicals (WHO-NNB). Available from: https:\/\/www.who.int\/immunization_standards\/vaccine_quality\/who_nnb\/en\/."},{"key":"10.1016\/j.vaccine.2019.07.088_b0095","unstructured":"WHO Collaboration \u2013 Global network of national vaccine control laboratories. WHO Drug Information, 2017;31(1):p. 3\u201310."},{"key":"10.1016\/j.vaccine.2019.07.088_b0100","unstructured":"WHO Regulatory networks \u2013 Update on the WHO-National Control Laboratory Network for Biologicals. WHO Drug Information 2018;32(2):p. 189\u201393."},{"key":"10.1016\/j.vaccine.2019.07.088_b0105","first-page":"97","article-title":"Transferability study of CHO cell clustering assays for monitoring of pertussis toxin activity in acellular pertussis vaccines","volume":"2015","author":"Isbrucker","year":"2016","journal-title":"Pharmeur Bio Sci Notes"},{"key":"10.1016\/j.vaccine.2019.07.088_b0110","unstructured":"WHO Standard Operating Procedure: Mutant Analysis by PCR And Restriction Enzyme Cleavage (MAPREC) for Oral Poliovirus (Sabin) Vaccine Types 1, 2 or 3 Version 5 (2012). Available from: https:\/\/www.who.int\/biologicals\/vaccines\/MAPREC_SOP_Final_09112012.pdf"},{"key":"10.1016\/j.vaccine.2019.07.088_b0115","unstructured":"WHO Recommendations to assure the quality, safety and efficacy of tetanus vaccines (adsorbed) Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No. 927. WHO Technical Report Series No. 980, 2014 Annex 5."},{"key":"10.1016\/j.vaccine.2019.07.088_b0120","unstructured":"WHO Recommendations to assure the quality, safety and efficacy of diphtheria vaccines (adsorbed) Replacement of Annex 2 of WHO Technical Report Series, No. 800, and Annex 5 of WHO Technical Report Series, No. 927. WHO Technical Report Series No. 980, 2014 Annex 4."},{"key":"10.1016\/j.vaccine.2019.07.088_b0125","unstructured":"NIBSC & WHO International Standard - Sabin Inactivated Polio Vaccine (sIPV). Instructions for use - Version 2.0; Available from: https:\/\/www.nibsc.org\/documents\/ifu\/17-160.pdf."},{"key":"10.1016\/j.vaccine.2019.07.088_b0130","unstructured":"AVAREF Publications: Guideline for Joint and Assisted Reviews of Clinical Trial Applications. AVAREF 2017-JRCTA; Available from: http:\/\/afro.who.int\/about-us\/leadership\/avaref."},{"issue":"6","key":"10.1016\/j.vaccine.2019.07.088_b0135","doi-asserted-by":"crossref","first-page":"588","DOI":"10.26719\/2018.24.6.588","article-title":"Joint evaluation of marketing authorization files of inactivated polio vaccines in countries of the Eastern Mediterranean Region","volume":"24","author":"Langar","year":"2018","journal-title":"East Mediterr Health J"},{"key":"10.1016\/j.vaccine.2019.07.088_b0140","doi-asserted-by":"crossref","unstructured":"Dellepiane N, Pagliusi S, and Registration Experts Working Group., Challenges for the registration of vaccines in emerging countries: differences in dossier requirements, application and evaluation processes. Vaccine 2018;36(24):p. 3389\u201396.","DOI":"10.1016\/j.vaccine.2018.03.049"},{"key":"10.1016\/j.vaccine.2019.07.088_b0145","unstructured":"European Commission. EU Volume 2 B Notice to applicants. Medicinal products for human use. Presentation and format of the dossier. Common Technical Document (CTD). Available from: https:\/\/ec.europa.eu\/health\/documents\/eudralex\/vol-2_en."},{"key":"10.1016\/j.vaccine.2019.07.088_b0150","unstructured":"UNICEF Supply Annual Report 2017. Available from: https:\/\/www.unicef.org\/supply\/files\/Unicef_External_Annual_Report_2017.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19310096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T03:48:28Z","timestamp":1664164108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19310096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19310096"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}